18th Oct 2017 11:47
18 October 2017
Grant of Share Options
Clinigen Group plc (AIM: CLIN, the "Company"), announces that, on 16 October 2017, the following Directors and PDMR's were granted share options over a total of 94,676 ordinary shares of 0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 16 October 2020 subject to the achievement of certain performance criteria.
Director/PDMR | Number of share options granted | Total number of share options now held |
| Total number of ordinary shares now held | Total number of ordinary shares (excluding share options) as % issued share capital |
Shaun Chilton | 34,904 | 274,790 |
| 312,943 | 0.27% |
Martin Abell | 23,996 | 183,810 |
| 19,404 | 0.02% |
Steve Glass | 17,888 | 123,725 |
| 17,360 | 0.02% |
Debra Ainge | 17,888 | 48,518 |
| 10,254 | 0.01% |
-Ends-
Contact details
Clinigen Group plc | Tel: +44 (0) 1283 495010 |
Shaun Chilton, Group Chief Executive Officer | |
Martin Abell, Group Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) James Black / Tom Ballard (Corporate Broking) | |
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood | |
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw | Email: [email protected] |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L